Results 81 to 90 of about 37,607 (177)

Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China. [PDF]

Front Pharmacol
Weng J, Liu N.
europepmc   +1 more source

Biological patent thickets and delayed access to biosimilars, an American problem. [PDF]

J Law Biosci, 2022
Goode R, Chao B.
europepmc   +1 more source

CORR Insights®: Do Patients of Different Levels of Affluence Receive Different Care for Pediatric Osteosarcomas? One Institution's Experience. [PDF]

Clin Orthop Relat Res
Morris CD.
europepmc   +1 more source

When speed matters: a discussion on the benefits of a grace period in patent law to accelerate pharmaceutical innovation in times of pandemic. [PDF]

J Law Biosci, 2022
Ozyhar T, Barnabei L, Myrick D.
europepmc   +1 more source

Intellectual property rights over 'integrated' medical devices: the potential health impacts and bioethical implications of rightsholders' control. [PDF]

Med Law Rev
McMahon AM, Kolawole OI.
europepmc   +1 more source

Blockchain-Based Information Security Protection Mechanism for the Traceability of Intellectual Property Transactions. [PDF]

Sensors (Basel)
Wang Z, Feng W, Huang M, Feng S, Mo S, Li Y.   +5 more
europepmc   +1 more source

Judicial improvement, market integration, and export technical complexity-a quasi-natural experiments based on the creation of circuit courts. [PDF]

PLoS One
Gao X, Kong S.
europepmc   +1 more source

The Legislative Approach and System Improvement of China's Compulsory Licensing for Drug Patents. [PDF]

Drug Des Devel Ther, 2021
Cao Z, Chen Y, Jiang W, Li W.
europepmc   +1 more source

Exploring perspectives of the Unified Patent Court and Unitary Patent within the business and legal communities [PDF]

, 2014
Intellectual Property Office, McDonagh, L.   +1 more
core  

Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs. [PDF]

Pharm Pat Anal
Niazi SK.
europepmc   +1 more source